// App-Quantinova.ai

TCT-436 : Multi-Center, Post-marketing Evaluation of the Elixir DESolve Novolimus Eluting Bioresorbable Coronary Stent System: 6-month Results from the DESolve PMCF Study

Researchers

Presenter

  • Holger Nef

Principal Investigators

  • Karl Eugen Hauptmann

  • Azeem Latib

  • Lynn Morrison

  • Sara Toyloy

  • Lynn Vandertie

  • Antonio Colombo

Medical Centers

  • Universtitatsklinikum Essen AoR, Essen, Germany

  • Elixir Medical, sunnyvale, California, United States

  • Trier, Germany

  • Interventional Cardiology Institute San Raffaele Hospital, Milan, Italy

  • Medical Device Consultancies, Christ Church, New Zealand

Locations

  • United States

  • Germany

  • Italy

  • New Zealand

Companies

  • Elixir medical corpo

Study Components

Therapeutic Area

  • Cardiovascular (CVS)

Disease

  • Coronary artery lesions

  • Hypercholesterolemia, Familial, 1

  • Angina

  • Hypertension

  • Venous thrombosis

Biomarkers

  • Serine/threonine-protein kinase mTOR

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved